NCT04825860: A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase |
|
|
| Terminated | 2/3 | 83 | Japan, RoW | SEP-363856 50 mg, SEP-363856 75 mg, Placebo | Sumitomo Pharma Co., Ltd. | Schizophrenia | 10/23 | 10/23 | | |